Cynata Therapeutics has lifted its proposed shareholder-approved placement to approximately $750,000, taking potential proceeds from its two-stage capital raising to about $1.663 million before costs. The biotech says key clinical and termination costs have been paid, while its externally funded kidney transplant trial remains in follow-up.
- Proposed placement increased from approximately $550,000 to $750,000
- Total potential proceeds from the placement and entitlement offer reach approximately $1.663 million before costs
- Placement remains subject to shareholder approval at a general meeting expected in January 2027
- NEREID trial's second cohort has completed treatment and is awaiting DSMB review
- Cynata is evaluating further Cymerus development and potential new asset opportunities
Proposed Placement Grows to $750,000
Cynata Therapeutics Limited (ASX:CYP) has increased its proposed placement by roughly $200,000 after receiving additional commitments from sophisticated investors, taking the planned raise to approximately $750,000 before costs. The transaction would issue about 75 million shares at $0.01 each, subject to shareholder approval.
The expanded placement follows the completed $913,000 entitlement offer, which was underwritten after eligible shareholders subscribed for only part of the offer. If approved, the two raisings would generate approximately $1.663 million before costs.
Shareholder Vote Still Required
The placement will carry one free attaching option for every three shares issued. Those options will have a $0.02 exercise price and expire on 3 May 2029, matching the terms of the options issued under the entitlement offer. Caravel Securities will receive a 6% placement fee and 8.2 million options, with the fee-option allocation increased from 6 million to reflect the larger transaction.
Cynata expects to seek approval for the shares, attaching options and fee options at a general meeting in January 2027. The company says the funds will support placement costs, working capital and potential transactions to secure rights to new pharmaceutical or biotechnology assets. It also states that none of the additional approximately 20 million shares will be issued to related parties.
NEREID Trial Awaits Second Cohort Review
Cynata says all material costs linked to its recently completed Cymerus clinical trials and the termination of employee and service-provider agreements have been paid. Its Cymerus intellectual property portfolio, including licence agreements, patents and cell lines, is being maintained while the board assesses possible development pathways.
The externally funded Phase 1/2 NEREID kidney transplant trial, managed and funded by Leiden University Medical Centre, remains active. Treatment and enrolment for the second cohort are complete, with three patients undergoing follow-up after receiving two infusions of CYP-001 alongside standard treatment. An independent Data and Safety Monitoring Board review is due once the final patient has completed six weeks of follow-up; the company says it will announce the review outcome when received.
Bottom Line?
The January approval vote is the immediate financing gate, while the second NEREID cohort review remains the clearest clinical catalyst. Neither the filing nor the trial update establishes an efficacy outcome for that cohort.
Questions in the middle?
- Will shareholders approve the expanded placement and its associated options in January 2027?
- What will the DSMB conclude after the second NEREID cohort completes the required follow-up?
- Can Cynata convert its maintained Cymerus platform and new-asset search into a defined development or licensing opportunity?